No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Analysts at Berenberg nudged up their target price on 'sell'-rated Rentokil from 284p to 300p on Tuesday, but still warned that underinvestment was threatening mid-term growth.
Rentokil reported its third-quarter revenue and growth figures in late October, and Berenberg noted that while the stock rallied due to accelerated organic growth of 1.8% yoy in US Pest Control, up from 0.3% year-on-year in Q2, it said the beat was driven by strong one-off jobs, likely due to a warm summer in the US, which will reverse to more normalised levels in Q4, in its view.
Berenberg also noted that organic growth from contract revenue continued to appear "weak", while International division organic growth fell short of expectations.
"The reporting period solidifies our bearish view of Rentokil, with upcoming headwinds to growth and profitability through the resumption of integrating Terminix likely to lead to pressure on employee retention, alongside a need for investment to improve service levels," said Berenberg.
"Our 'sell' call has clearly been at odds with investor sentiment. In our view, strategies employed thus far by Rentokil cannot meaningfully move volume growth into positive territory, as strategies do not relate to the improvement of service levels, essential to the bull thesis."
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.